Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.
| Company | Change | P/E (TTM) |
|---|---|---|
CERSCerus Corp. | +6.44% | - |
KEQUKewaunee Scientific Corp. | - | 14.29 |
SPANSpan-America Medical Systems Inc. | -0.64% | 11.76 |
HAEHaemonetics Corp. | -0.25% | - |
SYKStryker Corp. | -0.03% | 25.86 |
RSCFReflect Scientific Inc. | -1.67% | 4.28 |
Cesca Therapeutics, Inc. engages in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It offers a therapeutic technology platform, SurgWerks, an intraoperative rapid system for harvesting, selection,...
| Q4 2016 Estimate Trends | |
|---|---|
| Current: | $-1.15 |
| 1 month ago: | $0.43 |
| 3 months ago: | $0.60 |
| Q1 2017 Estimate Trends | |
|---|---|
| Current: | $- |
| 1 month ago: | $- |
| 3 months ago: | $- |
| Mar 2016 | 5-quarter trend | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Growth | -126.00% | | ||||||||||
| Sales or Revenue | 2.83 M | | ||||||||||
| Sales or Revenue Growth | -29.94% | | ||||||||||
| EBITDA | - | | ||||||||||
| 2015 | 5-year trend | |||||||||||
| Net Income Growth | -72.08% | | ||||||||||
| Sales or Revenue | 16.04 M | | ||||||||||
| Sales or Revenue Growth | +0.34% | | ||||||||||
| EBITDA | -13.51 M | |